

**Emmanouil Dermitzakis, PhD**

CEO and co-founder of Antithesis Therapeutics

Emmanouil (Manolis) Dermitzakis is currently CEO and co-founder of Antithesis Therapeutics. In the past, he was VP and Head of Computational Biology at GSK, Professor of Genetics in the Department of Genetic Medicine and Development, University of Geneva Medical School, Founding Director of the Health2030 Genome Center and Director of the Institute of Genetics and Genomics in Geneva. He was vice-chair of the Swiss Personalized Health Network Genomics Task Force, and also member of the Swiss Institute of Bioinformatics. He previously served as Chairman of the National Council for Research, Technology and Innovation and advisor to the Prime Minister in Greece. He also served as president of the World Hellenic Biomedical Association (2014-2015). He obtained his B.Sc. (1995) and M.Sc. (1997) from the University of Crete (Greece) and his PhD in 2001 from the Pennsylvania State University in the USA. His post-doctoral work was at the University of Geneva Medical School. He previously was a Senior Investigator at the Wellcome Sanger Institute in Cambridge. He was elected EMBO member in 2014, recipient of the 2017 Bodossakis science award, has been named Highly Cited Researcher by ISI every year since 2014 and he was the recipient of the Curt Stern award from the American Society of Human Genetics in 2021. His research has been funded by the Swiss NSF, the NIH, the ERC and the Wellcome Trust among others. His research focuses on the genetic causes and mechanisms of human disease. He has had leading roles in the ENCODE, Mouse Genome Sequencing, the International HapMap, the 1000 genomes and GTEx projects. He has served in the Board of scientific journals such as Science, eLIFE, PLoS Genetics and as Chief Editor in Frontiers in Genetics.